Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

The company reported a cash position of $341.5 million, expected to fund planned operations through 2027.

– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company plans to initiate dosing in Phase 3 trials in both severe asthma and CRSwNP in Q1 2027 – – Reported positive top-line results from Phase 2 VALIANT trial of verekitug in patients with severe asthma in February 2026, demonstrating significant improvements in asthma exacerbations and lung function – – Presented additional analyses from Phase 2 VIBRANT trial at AAAAI, reinforcing verekitug's therapeutic potential in CRSwNP – – Strong cash position of $341.5 million expected to fund planned operations through 2027 – WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted its Phase 3 development strategy for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses , including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001) – WALTHAM, Mass., March 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented additional data from the Phase 2 VIBRANT clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP).

– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session –

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in March:

Upstream Bio Inc. (NASDAQ: UPB) shares are trading lower during Friday's session as the stock reacts to recent developments in its clinical trials.

Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent dosing regimen.